Cellectis S.A. CLLS
Cellectis S.A. (Nasdaq: CLLS) is a cardio-renal-metabolic drug developer. Its lead program, .HEAL-101, is in Pre-clinical for severe hypertriglyceridemia (in vivo APOC3 base editing). Its next catalyst on record is .HEAL-101: Preliminary Phase 1 IIT data (China) (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: .HEAL-101 — Preliminary Phase 1 IIT data (China) (H2 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| .HEAL-101 | severe hypertriglyceridemia (APOC3 TALE base editor, LNP) | gene therapy | Pre-clinical |
| .HEAL-201 | severe hypercholesterolemia (PCSK9 epigenetic editor, LNP) | gene therapy | Pre-clinical |
Recent results and decisions
- Aug 6, 2026positive BALLI-01 full Phase 1 at EHA 2026: target Phase 2 population ORR 100% (7/7), CR/CRi 57% (4/7), 75% MRD-negative; Gr>=3 CRS and ICANS each 4%.
In the target Phase 2 population, an overall response rate (ORR) of 100% (7/7) was achieved with a complete remission/complete remission with incomplete count recovery (CR/CRi) rate of 57% (4/7), of whom 75% achieved minimal residual disease (MRD) negative status.
Filing - Aug 6, 2026positive NATHALI-01 translational data at EHA 2026: optimal dose cohort (n=8) ORR 88%, CR 63%.
In the optimal dose cohort (n=8), ORR and complete response (CR) were 88% and 63%, respectively.
Filing - Aug 6, 2026positive ALPHA3 interim futility analysis (Allogene): MRD negativity 58.3% (7/12) with cema-cel vs 16.7% (2/12) with observation.
showed that 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity compared to 16.7% (2/12) in the observation arm, representing a 41.6% absolute difference in MRD clearance between the arms
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.